Biotech company and anemia drugmaker Amgen Inc. reported higher than expected third quarter profit Tuesday, helped by sales of its rheumatoid arthritis drug Enbrel, which increased 17%. Profit more than doubled to $1.1 billion, or $1.41 per share, compared to $454 million, or 50 cents per share, in its first quarter led by CEO Robert Bradway. Revenue for the quarter rose 10% to $4.32 billion.
"Our business has very good momentum," Bradway said in a conference call.
Anemia drug sales
• Aranesp (darbepoetin alfa) sales decreased 17%
• Epogen (epoetin alfa) sales increased 3%, beating expectations.